Adjuvant Vaccine Combo May Prolong Survival in Melanoma
Source: Oncology Nursing News, April 2024
A multipeptide vaccine combination approach may extend survival in stage IIB to IV melanoma.
Patients with stage IIB to IV melanoma who received adjuvant treatment with a CD8-positive T cell-targeted multipeptide vaccine (12MP) with a CD4-positive T cell-directed 6 melanoma-specific helper peptides (6MHP) vaccine exhibited prolonged survival compared with 12MP plus a nonspecific helper peptide vaccine from tetanus toxoid (tet), according to findings from a post-hoc analysis.
The post-hoc analysis of a phase 2 clinical trial (NCT00118274) published in Nature Communications also showed that benefit appeared confined to male patients.